Scarica l'app Stockscreener
16.80
6.19%
0.98
Dopo l'orario di chiusura:
16.68
-0.12
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com India
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com India
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
KalVista Pharmaceuticals (KALV) Receives Buy Rating with Increas - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch - Investing.com UK
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart - MSN
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY - Investing.com Canada
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY - Investing.com Australia
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - The Joplin Globe
Will KalVista Pharmaceuticals Inc. (4XC1) stock sustain bullish trend into 2025Weekly Gains Summary & Weekly Breakout Watchlists - ulpravda.ru
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessions - bollywoodhelpline.com
Aug Sectors: Is KalVista Pharmaceuticals Inc stock supported by innovation pipeline2025 Retail Activity & Technical Buy Zone Confirmation - moha.gov.vn
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
KalVista Pharmaceuticals, Inc.Common Stock (NQ: KALV - FinancialContent
KalVista Pharmaceuticals (KALV) Gains Approval for EKTERLY in Ja - GuruFocus
Japan approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Canada
KalVista (KALV) Gains Approval for Ekterly in Japan - GuruFocus
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. stock attract ESG investors2025 Sector Review & Smart Money Movement Tracker - Улправда
KalVista Pharmaceuticals Earnings Notes - Trefis
KalVista Shares Navigate Post-Rally Consolidation Phase - AD HOC NEWS
Sentiment Review: How KalVista Pharmaceuticals Inc. (4XC1) stock expands through international marketsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Why KalVista Pharmaceuticals Inc. stock is favored by pension funds2025 Bull vs Bear & Free Community Consensus Stock Picks - DonanımHaber
Can KalVista Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - DonanımHaber
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV) and Novan (NOVN) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year HighHere's Why - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC - MarketBeat
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Stonepine Capital Management LLC - MarketBeat
Saturn V Capital Management LP Sells 192,267 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):